The Inhibitor of Prothrombin Conversion in Plasma of Patients on Oral Anticoagulant Treatment

R M Bertina; M E J Westhoek-Kuipers; G H J Alderkamp

doi:10.1055/s-0038-1650178

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1981; 45(03): 237-241
DOI: 10.1055/s-0038-1650178

Original Article

Schattauer GmbH Stuttgart

The Inhibitor of Prothrombin Conversion in Plasma of Patients on Oral Anticoagulant Treatment

Authors

R M Bertina

The Haemostasis and Thrombosis Research Unit, Leiden University Hospital, Leiden, The Netherlands
M E J Westhoek-Kuipers

The Haemostasis and Thrombosis Research Unit, Leiden University Hospital, Leiden, The Netherlands
G H J Alderkamp

The Haemostasis and Thrombosis Research Unit, Leiden University Hospital, Leiden, The Netherlands

Abstract

PDF Download

Summary

Pooled plasma of patients under stable oral anticoagulation has been analysed with respect to the presence of the vitamin-K dependent factors (factors II, VII, IX and X). Of all factors 1.5-2 times more antigen than procoagulant activity was present. The concentration of factors II, X (measured spectrophotometrically) and VII is about 0.25 U/ml while factor IX is slightly higher. Coagulation assays of factor X always gave lower values than the spectrophotometric assay. This discrepancy was not influenced by the removal of either factor II-factor VII- or factor IX antigen. However, when the factor X antigen was replaced by normal factor X, all factor X assays gave identical results, indicating that PIVKA X is responsible for these discrepancies. Using the technic of the Thrombotest-dilution curve it was shown that PIVKA X is the factor that causes the abnormal prolongation of ox-brain prothrombin time in these plasmas.

Keywords

Oral anticoagulation - PIVKA X - Inhibitor

PDF (1080 kb)

References

References
1 Hemker HC, Veltkamp JJ, Hensen A, Loeliger EA. Nature of prothrombin biosynthesis: preprothrombinaemia in vitamin-K deficiency. Nature 1963; 200: 589-590
2 Loeliger EA, Esch B, van der, Mattem MJ, Brabander ASAden. Behaviour of factors II, VII, IX and X during long-term treatment with coumarin. Thromb Diath Haemorrh 1963; 09: 74-89
3 Loeliger EA, Hensen A, Mattem MJ, Hemker HC. Behaviour of factors II, VII, IX and X in bleeding complications during long-term treatment with coumarin. Thromb Diath Haemorrh 1964; 10: 278-281
4 Owren PA. Tests for control of anticoagulant therapy. Thromb Diath Haemorrh 1964; S13: 371-378
5 Hemker HC, Siepel TV, Altman R, Loeliger EA. Kinetic aspects of the interaction of blood clotting enzymes. II. The relation between clotting time and plasma concentration in prothrombin-time estimations. Thromb Diath Haemorrh 1967; 17: 349-357
6 Hemker HC, Veltkamp JJ, Loeliger EA. Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb Diath Haemorrh 1968; 19: 346-363
7 Girolami A, Dal BoZanon R, Sticchi A. Apparent “inhibition” as tested by means of the dilution curve system in patients with clotting defect due to liver damage. Blut 1977; 35: 247-252
8 Larrieu MJ, Meyer D. Abnormal factor IX during anticoagulant treatment. Lancet 1970; 02: 1085
9 Denson KWE. The levels of factors II, VII, IX and X by antibody neutralization techniques in the plasma of patients receiving phenindione therapy. Br J Haematol 1971; 20: 643-648
10 Prydz H, Gladhaug Å. Factor X immunological studies. Thromb Diath Haemorrh 1971; 25: 157-165
11 Veltkamp JJ, Muis H, Muller AD, Hemker HC, Loeliger EA. Additional evidence for the existence of a precursor molecule of the prothrombin complex in oral anticoagulants. Thromb Diath Haemorrh 1971; 25: 312-315
12 Thompson AR. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B. J Clin Invest 1977; 59: 900-910
13 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
14 Ganrot PO, Niléhn JE. Plasma prothrombin during treatment with dicumarol. II. Demonstration of an abnormal prothrombin fraction. Scand J Clin Lab Invest 1968; 22: 23-28
15 Ørstavik KH, Laake K. Factor IX in warfarin treated patients. Thromb Res 1978; 13: 207-218
16 Bertina RM, Veltkamp JJ. A genetic variant of factor IX with decreased capacity for Ca²⁺binding. Br J Haematol 1979; 42: 623-635
17 Prydz H. Vitamin K-dependent clotting factors. Semin Thromb Hemostas 1977; 4: 1-14
18 Suttie JW. The metabolic role of vitamin K. Fed Proc 1980; 39: 2730-2735
19 Stenflo J, Femlund P, Egan W, Roepstorff P. Vitamin-K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71: 2730-2733
20 Reekers PPM, Lindhout MJ, Kop-Klaassen BH M, Hemker HC. Demonstration of three anomalous plasma proteins induced by a vitamin K antagonist. Biochim Biophys Acta 1973; 317: 559-562
21 Lindhout MJ, Kop-Klaassen BH, Kop JM M, Hemker HC. Purification and properties of phenprocoumon-induced decarboxy-factor X from bovine plasma. Comparison to normal factor X. Biochem Biophys Acta 1978; 533: 302-317
22 Loeliger EA, Halem-Visser LP van. Biological properties of the thromboplastins and plasmas included in the ICTH/ICSH collaborative study on prothrombin time standardization. Thromb Haemostas 1979; 42: 1115-1127
23 Girolami A, Celia G, Patrassi GM, Dal BoZanon R, Fabris F. About the significance or insignificance of coumarin-induced pre-factors. Thromb Haemostas 1980; 43: 225
24 Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders. I. Thromb Diath Haemorrh 1968; 19: 279-303
25 Owren PA. A quantitative one stage method for the assay of prothrombin. Scand J Clin Lab Invest 1949; 19: 81-83
26 Bertina RM, Marel-van NieuwkoopW van der, Loeliger EA. Spectrophotometric assays of prothrombin in plasma of patients using oral anticoagulants. Thromb Haemostas 1979; 42: 1296-1305
27 Bertina RM, Loeliger EA. The potential use of chromogenic assays in the routine monitoring of oral anticoagulant therapy. In: Lynen HP, Collen D, Verstraete M. (eds.), Synthetic substrates in clinical blood coagulation . Martinus Nijhoff Publishers; The Hague-Boston-London: 1980. p 13-23
28 Bertina RM, Linden IK van der. Inhibitor-neutralisation assay and electro-immuno assay of human factor IX (Christmas factor). Clin Chim Acta 1977; 77: 275-288
29 Bertina RM, Orlando M, Tiedemann-Alderkamp GH J. Preparation of a human factor VII deficient plasma. Thromb Res 1978; 13: 537-541
30 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
31 Loeliger EA, Halem-Visser LP van, Hemker HC. Plasma free of factors II, VII, IX and X, need for high speed centrifugation after A1 (OH)₃absorption. Thromb Diath Haemorrh 1973; 29: 211-212
32 Wijk EM van, Kahlé LH, Cate JW ten. Mechanized amidolytic technique for determination of factor X and factor-X antigen, and its applications to patients being treated with oral anticoagulants. Clin Chem 1980; 26: 885-890
33 Kisiel W. Human plasma protein C. Isolation, characterization, and mechanism of activation by α-thrombin. J Clin Invest 1979; 64: 761-769
34 Di ScipioRG, Davie EW. Characterization of protein S, a γ-carboxy-glutamic acid containing protein from bovine and human plasma. Biochemistry 1979; 18: 899-904
35 Prowse CV, Esnouf MP. The isolation of a new warfarin sensitive protein from bovine plasma. Biochem Soc Trans 1977; 05: 255-265
36 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thromb Diath Haemorrh 1958; 02: 24-38
37 Hemker HC, Swart AC W, Alink AJ M. Artificial reagents for factor VII and factor X, a computer programme for obtaining reference tables for one-stage determinations in the extrinsic system. Thromb Diath Haemorrh 1972; 27: 205-211